Triple
T18644843
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Novo Nordisk |
E455777
|
entity |
| Predicate | majorProduct |
P7216
|
FINISHED |
| Object | Tresiba |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Tresiba | Statement: [Novo Nordisk, majorProduct, Tresiba]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tresiba Context triple: [Novo Nordisk, majorProduct, Tresiba]
-
A.
Levemir
Levemir is a long-acting insulin analog used to help control blood sugar levels in people with diabetes.
-
B.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
C.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
E.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tresiba Target entity description: Tresiba is a long-acting insulin medication used to improve blood sugar control in people with diabetes.
-
A.
Levemir
Levemir is a long-acting insulin analog used to help control blood sugar levels in people with diabetes.
-
B.
Trulicity
Trulicity is a prescription GLP-1 receptor agonist medication used to improve blood sugar control in adults with type 2 diabetes.
-
C.
Rybelsus
Rybelsus is an oral semaglutide medication used to improve blood sugar control in adults with type 2 diabetes.
-
D.
Farxiga
Farxiga is a prescription SGLT2 inhibitor medication used primarily to treat type 2 diabetes and reduce the risk of cardiovascular and kidney complications.
-
E.
Ozempic
Ozempic is a prescription semaglutide medication primarily used to improve blood sugar control in adults with type 2 diabetes and widely known for its weight-loss effects.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8d38ea1e88190997e9b231190ba6f |
completed | April 10, 2026, 10:40 a.m. |
| NER | Named-entity recognition | batch_69e5500c36188190bfdd7aca73f3c006 |
completed | April 19, 2026, 9:58 p.m. |
Created at: April 10, 2026, 11:47 a.m.